SLRX Archives - BioTuesdays

Markets

Ladenburg cuts Salarius to neutral; removes PT

Ladenburg Thalmann downgraded Salarius Pharmaceuticals (NASDAQ:SLRX) to “neutral” from “buy” and removed its price target after the company disclosed it is exploring strategic alternatives and implement cost-cutting...

August 11, 2023

Markets

Ladenburg starts Salarius Pharma at buy; PT $3.80

Ladenburg Thalmann launched coverage of Salarius Pharmaceuticals (NASDAQ:SLRX) with a “buy” rating and price target of $3.80. The stock closed at 63 cents on April 24. Salarius obtained a NASDAQ listing through a...

April 27, 2020

Feature

Salarius Pharmaceuticals targeting epigenetic causes of cancers

Salarius Pharmaceuticals (NASDAQ:SLRX) is poised to ride the growing epigenetic wave with a differentiated lead drug candidate, seclidemstat, in early clinical development for the treatment of Ewing sarcoma and advanced...

October 22, 2019

Developments

Salarius adds two clinical sites to seclidemstat trial in Ewing Sarcoma

Salarius Pharmaceuticals (NASDAQ:SLRX) added Memorial Sloan Kettering Cancer Center in New York City and Nationwide Children’s Hospital in Columbus, OH as clinical trial sites in its ongoing Phase 1/2 clinical trial of...

October 8, 2019

Developments

Salarius achieves dose-escalation milestones in sarcoma and solid tumor trials

The Safety Review Committees overseeing Salarius Pharmaceuticals’ (NASDAQ:SLRX) Phase 1/2 clinical study of Seclidemstat in Ewing sarcoma and the Phase 1 study of Seclidemstat in patients with advanced solid tumors...

September 25, 2019

Executive Moves

Salarius Pharma names Scott Jordan as CBO; Mark Rosenblum as EVP finance and interim CFO

Salarius Pharmaceuticals (NASDAQ:SLRX) has appointed Scott Jordan as chief business officer (CBO) and Mark Rosenblum as EVP finance and interim CFO. Mr. Jordan has been Salarius’ CFO since 2016. As CBO, he will lead...

September 13, 2019

Tag - SLRX